Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
Dr. med. Andrea Klein, Univesitäts-Kinderspital beider Basel (UKBB)
Abstract (Lay summary see below)
Facilitation of trial participation for Swiss patients in Switzerland has been our aim for the last 10 years. The creation of a well-functioning registry has helped to include patients in studies in Switzerland and abroad (Paris, Freiburg i.B.). Large multinational studies have most often not had a study site in Switzerland because of high costs, complicated extra regulatory hurdles for few extra patients, not enough trial experience in the centers.
I have been approached by a pharmaceutical company to conduct a Phase 1 / 2 study in infants with spinal muscular atrophy type 1 (SMA1) as a principal investigator at the UKBB. This devastating disease is very rare and until very recently these patients were treated with palliative care and often died before the age of 1 year. Diagnosis is usually made at the age of 4-6 months. Patients can be included if <7 months old. This leaves only few weeks between the diagnosis and the possible inclusion into the trial. The rarity and short time between diagnosis and possible inclusion into the study makes planning ahead impossible. Therefore, the trial team needs to be ready even if there is no diagnosed patient. The study is very intense with strictly scheduled patient visits every 2-4 weeks with additional home visits. These infants are very sick and fragile and complications will be frequent. The pharmaceutical company covers costs per included patient, but not for trial readiness.
At the UKBB there is an outpatient trial center; Prof. Dirk Fischer at the UKBB, an adult neurologist, has experience with several studies in Duchenne and one in older SMA patients. He has a team of adult neurologists with trial experience and a study coordinator who are available as a resource for the planned SMA1 study. To conduct this trial an additional pediatric neurologist /experienced pediatrician has to be recruited. This person needs to be employed as soon as the study site is opened to be ready to include a patient as soon as the diagnosis is made.
Lay summary
Klinische Studien in der Schweiz zu ermöglichen und damit die Teilnahme von Schweizer Patienten an klinischen Studien zu erleichtern ist seit Jahren das Ziel. Um das zu erreichen wurde das Register für Spinale Muskelatrophie und Muskeldystrophie Duchenne aufgebaut. Durch das Register konnten bereits viele Schweizer Patienten an Studien teilnehmen, aber hauptsächlich im Ausland. Die Gründe dafür, dass viele grosse Studien kein Studienzentrum in der Schweiz haben sind die höheren Kosten im Vergleich zu den Nachbarländern, zusätzliche regulatorische Hürden für vergleichsweise kleine Patientenzahlen sowie mangelnde Studienerfahrung.
Um die grossen Pharmastudien durchführen zu können braucht es ein Studienteam von in Studiendurchführung ausgebildeten Ärzten, Physiotherapeutinnen, Koordinatorinnen und speziell ausgebildetes Pflegepersonal. Neuropädiater mit Erfahrung in dem Spezialgebiet der neuromuskulären Erkrankungen gibt es in der Schweiz nur sehr wenige, noch weniger mit Studienerfahrung. Es herrscht Nachwuchsmangel sowohl in der allgemeine Neuropädiatrie aber noch viel mehr im komplexen, sich rasch weiter entwickelnden Gebiet der neuromuskulären Erkrankungen. Es gibt nur wenige Ausbildungsstellen in Neuropädiatrie und die Ärzte sind ausgelastet mit klinischer Arbeit und sehen selten Kinder mit neuromuskulären Krankheiten.
Die vorgesehen Studie ist für Patienten mit Spinaler Muskelatrophie Typ 1, einer Erkrankung die in den ersten 6 Lebensmonaten auftritt und sehr rasch progredient ist. Die Erkrankung ist sehr selten und zwischen Diagnosestellung und möglichem Studieneinschluss gibt es nur sehr wenig Zeit, was eine Vorausplanung unmöglich macht. Eine pädiatrisch und neuropädiatrisch ausgebildete Studienärztin muss also bereit sein, um die plötzliche erhebliche Mehrarbeit leisten zu können. Mit der Unterstützung der FSRMM ist es nun möglich eine junge interessierte Studienärztin zu 20% anzustellen, die bis zum Einschluss eines Patienten und während der Studiendurchführung ausgebildet werden kann. Die Arbeit, die für die Studienpatienten anfällt wird von der Firma, die die Studie sponsert bezahlt. So ist es mit der Unterstützung der FSRMM möglich ein Studienteam mit neuropädiatrischer Expertise aufzubauen, was hoffentlich die Schweiz als Studienzentrum für weitere grosse Pharma gesponserte Studien attraktiver macht. Als Nebeneffekt unterstützt es die Suche nach Nachwuchs im Bereich der pädiatrischen Neuromuskulären Erkrankungen.
Projekte
- Neue Forschungsprojekte ab 2024
- Die Bedeutung der Forschung
- Finanzierte Projekte
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Projektbroschüre
- SEAL Therapeutics AG
- Meetings und Seminare
- Teilnahme an Dachverbände
- Patientenregister
- Netzwerk Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch